Clinical Trial of CD19 CAR-T Cell Therapy with non-virus Vector System

被引：0
|
作者：
Takahashi, Yoshiyuki [1 ]
机构：
[1] Nagoya Univ, Dept Pediat, Nagoya, Aichi, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY5-1
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [31] Gammaretroviral Vector CD19 CAR-T Manufactured in the Cocoon® Platform: An Automated and Closed Workflow
    Purpura, Kelly A.
    Malka, Rivka Gal
    Jacoby, Elad
    Avigdor, Abraham
    Rodin, Anastasia
    Brayer, Hadar
    Morrissey-Scoot, James
    Fargo, Karen
    Vicentini-Hogan, Michele
    Ostrout, Nicholas
    Hewitt, Matthew
    Abraham, Eytan
    Trainor, Nuala
    Besser, Michal
    MOLECULAR THERAPY, 2021, 29 (04) : 416 - 416
  • [32] Automated Generation and Phenotypic Characterization of Clinical Grade CD19 CAR-T Cells
    Sharma, Ashish
    Roe, Anne
    Lopes, Filipa Blasco
    Liu, Ruifu
    Reese, Jane
    Ribeiro, Susan Pereira
    Sekaly, Rafick-Pierre
    de Lima, Marcos
    Wald, David
    BLOOD, 2018, 132
  • [33] IMPACT OF INTESTINAL MICROBIOTA IN PATIENTS WITH NON-HODGKIN LYMPHOMA ON THE RESPONSE TO CAR-T CD19 THERAPY
    Roberto, Garcia-Vicente
    Alba, Rodriguez-Garcia
    Ruben, Gomez-Gordo
    Adriana, Ortega-Hernandez
    Sandra, Serrano
    Javier, Modrego
    Alejandra, Leivas
    Antonio, Valeri
    Sanchez-Pina, Jose M.
    Liz, Paciello Maria
    Dulcenombre, Gomez-Garre
    Joaquin, Martinez-Lopez
    Maria, Linares
    HAEMATOLOGICA, 2021, 106 (10) : 63 - 63
  • [34] Single-Cell Transcriptomic Analysis of Myeloid Lineage Evolution from CD19 CAR-T Cell Therapy
    Cui, Yajuan
    Wang, Peilong
    Zhu, Hongkai
    Wang, Zhihua
    Zhang, Huifang
    Xu, Haodong
    Li, Ruijuan
    Sheng, Yue
    Peng, Hongling
    PATHOBIOLOGY, 2025,
  • [35] Continuous B cell destruction and regeneration is crucial for effective response to anti CD19 CAR-T cell therapy
    Nevo, Neta
    Milman, Neta
    Cooper, Tim J.
    Zuckerman, Tsila
    Shen-Orr, Shai S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 761 - 761
  • [36] Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B- Cell Lymphoma
    Luttwak, Efrat
    Flynn, Jessica R.
    Devlin, Sean M.
    Cassanello, Giulio
    Corona, Magdalena
    Dahi, Parastoo B.
    De Abia, Alejandro Luna
    Fein, Joshua
    Giralt, Sergio A.
    Landego, Ivan
    Lin, Richard J.
    Palomba, Maria Lia
    Parascondola, Allison
    Park, Jae H.
    Saldia, Amethyst
    Scordo, Michael
    Tomas, Ana Alarcon
    Shah, Gunjan L.
    Perales, Miguel-Angel
    Salles, Gilles
    Shouval, Roni
    BLOOD, 2023, 142
  • [37] Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell
    Nie, Esther H.
    Su, Yi-Jiun
    Baird, John H.
    Agarwal, Neha
    Bharadwaj, Sushma
    Weng, Wen-Kai
    Smith, Melody
    Dahiya, Saurabh
    Han, May H.
    Dunn, Jeffrey E.
    Kipp, Lucas B.
    Miklos, David B.
    Scott, Brian J.
    Frank, Matthew J.
    BLOOD ADVANCES, 2024, 8 (06) : 1474 - 1486
  • [38] Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience
    Walker, Bryan
    Zimmer, Andrea J.
    Stohs, Erica J.
    Lunning, Matthew
    Lyden, Elizabeth
    Abbas, Anum
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25
  • [39] Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell
    Ramos, Carlos A.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (01): : 1 - 2
  • [40] Reduced ABO blood group antibody titers in patients after CD19 CAR-T cell therapy
    Li, Qiang
    Yang, Zhihuan
    Fang, Kuo
    Wei, Shuning
    Sun, Jiali
    Liu, Wei
    Chen, Xiaojuan
    Huang, Wenyang
    Zhang, Guangji
    Shi, Yin
    Liu, Yuntao
    Gong, Xiaoyuan
    Liu, Fang
    Zhou, Xueli
    Wang, Jianxiang
    Wang, Ying
    BLOOD SCIENCE, 2023, 5 (01): : 62 - 65
12345